Ampio Pharmaceuticals, Inc. Press Releases

Get AMPE Alerts
*Delayed - data as of Aug. 29, 2014  -  Find a broker to begin trading AMPE now
Exchange: AMEX
Industry: Health Care
Community Rating:
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Filtered By
Ordered By

Letter to the Ampio Shareholders in Regard to the STEP Study and Ampio's plans for the Ampion™ BLA
8/25/2014 7:56:00 AM - PR Newswire

Ampio reports that due to temperature deviations below product specifications during shipments to the Ampion™ STEP Study clinical sites, release of data will be delayed
8/21/2014 7:56:00 AM - PR Newswire

Analysis Of Available Data From Optimeyes Study (Blinded And Open Label) Of Optina™ For The Treatment Of Diabetic Macular Edema (DME) Indicates Potential For Significant Clinical Benefit
8/20/2014 7:56:00 AM - PR Newswire

Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
8/19/2014 7:56:00 AM - PR Newswire

Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Six of the Trial
8/18/2014 8:00:00 AM - PR Newswire

Luoxis Broadens Global Research Network for RedoxSYS™ oxidation-reduction potential (ORP) diagnostic system; Announces 17 Studies Currently Underway and Additional 30 Studies Set to Begin in 2014
8/11/2014 8:00:00 AM - PR Newswire

Ampio announces positive results on the open label portion of the Multiple injection Study of Ampion™ in patients with osteoarthritis of the knee.
8/5/2014 8:00:00 AM - PR Newswire

Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion™ in the new facility.
7/30/2014 8:00:00 AM - PR Newswire

Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado
7/23/2014 8:00:00 AM - PR Newswire

Ampio Initiates Study of Multiple Injections of Ampion™ Into the Knees of Patients with OA of the Knee to Assess its Healing and Cartilage Regeneration Effects
6/30/2014 8:00:00 AM - PR Newswire

Ampio Pharmaceuticals, in Response to Positive Feedback, Closes Enrollment in the OptimEyes Study (Optina™) and Will Present the Data to the FDA for Guidance
6/25/2014 8:00:00 AM - PR Newswire

Ampio Pharmaceuticals Announces Appointment of Gregory A. Gould as Chief Financial Officer
6/5/2014 8:00:00 AM - PR Newswire